- Home
- AKYA
as 07-26-2024 4:00pm EST
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 116.6M | IPO Year: | 2021 |
| Target Price: | $7.21 | AVG Volume (30 days): | 201.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.88 - $7.06 | Next Earning Date: | 08-05-2024 |
| Revenue: | $93,573,000 | Revenue Growth: | 17.89% |
| Revenue Growth (this year): | 9.45% | Revenue Growth (next year): | 20.80% |
Stock Insider Trading Activity of Akoya BioSciences Inc. (AKYA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McKelligon Brian | AKYA | President and CEO | Jun 11 '24 | Sell | $2.08 | 7,500 | $15,630.00 | 224,733 | SEC Form 4 |
| McKelligon Brian | AKYA | President and CEO | Jun 6 '24 | Sell | $2.01 | 7,500 | $15,063.75 | 224,733 | SEC Form 4 |
| McKelligon Brian | AKYA | President and CEO | Mar 20 '24 | Sell | $4.97 | 7,500 | $37,242.75 | 231,868 | SEC Form 4 |
| McKelligon Brian | AKYA | President and CEO | Mar 13 '24 | Sell | $4.94 | 7,500 | $37,042.50 | 231,868 | SEC Form 4 |
| McKelligon Brian | AKYA | President and CEO | Mar 13 '24 | Sell | $4.94 | 7,500 | $37,035.00 | 224,368 | SEC Form 4 |
| McKelligon Brian | AKYA | President and CEO | Dec 19 '23 | Sell | $4.48 | 7,500 | $33,565.50 | 152,563 | SEC Form 4 |
| McKelligon Brian | AKYA | President and CEO | Dec 12 '23 | Sell | $4.25 | 7,500 | $31,871.25 | 152,563 | SEC Form 4 |
Latest Akoya BioSciences Inc. News
AKYA Breaking Stock News: Dive into AKYA Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
Simply Wall St.
15 days ago
While institutions own 21% of Akoya Biosciences, Inc. (NASDAQ:AKYA), private equity firms are its largest shareholders with 49% ownership
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Business Wire
a month ago
Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
Business Wire
a month ago
Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
GlobeNewswire
a month ago
SEALSQ to Launch Two New Quantum Resistant Chips
Compare AKYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKYA Akoya BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.